Myoinositol as a biomarker in recurrent glioblastoma treated with bevacizumab : a 1H-magnetic resonance spectroscopy study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: PLoS one, volume 11, issue 12, e0168113, doi:10.1371/journal.pone.0168113
- Schlagwort
-
Krebs
Onkologie
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2016
- Urheber
-
Steidl, Eike
Pilatus, Ulrich
Hattingen, Elke
Steinbach, Joachim Peter
Zanella, Friedhelm E.
Ronellenfitsch, Michael W.
Bähr, Oliver
- URN
-
urn:nbn:de:hebis:30:3-420028
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:42 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Steidl, Eike
- Pilatus, Ulrich
- Hattingen, Elke
- Steinbach, Joachim Peter
- Zanella, Friedhelm E.
- Ronellenfitsch, Michael W.
- Bähr, Oliver
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2016
Ähnliche Objekte (12)
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Bevacizumab for patients with recurrent multifocal glioblastomas
Procarbazine, carmustine and vincristine (PBV) in chemotherapy pre-treated patients with recurrent glioblastoma : a single-institution analysis
Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine
Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
The diversity of tumor-associated cells in primary and recurrent glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
Impact of resection on overall survival of recurrent Glioblastoma in elderly patients
Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Bevacizumab for patients with recurrent multifocal glioblastomas
Procarbazine, carmustine and vincristine (PBV) in chemotherapy pre-treated patients with recurrent glioblastoma : a single-institution analysis
Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine
Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
The diversity of tumor-associated cells in primary and recurrent glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
Impact of resection on overall survival of recurrent Glioblastoma in elderly patients
Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Bevacizumab for patients with recurrent multifocal glioblastomas
Procarbazine, carmustine and vincristine (PBV) in chemotherapy pre-treated patients with recurrent glioblastoma : a single-institution analysis
Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine
Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern
Adrenal insufficiency in patients with corticosteroid-refractory cerebral radiation necrosis treated with bevacizumab
ERGO: A pilot study of ketogenic diet in recurrent glioblastoma
The diversity of tumor-associated cells in primary and recurrent glioblastoma
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Age-adjusted Charlson comorbidity index in recurrent glioblastoma: a new prognostic factor?
Impact of resection on overall survival of recurrent Glioblastoma in elderly patients